U.S. FDA approves Biogen's hemophilia B drug Alprolix

Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. Hemophilia B is a rare, inherited disorder in which a person's blood does not clot properly, which can lead to prolonged bleeding and bruising. Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. Patients with hemophilia A lack or have reduced levels of coagulation factor VIII.



via Health News Headlines - Yahoo News http://ift.tt/1fugC8c